Windlas Biotech Ltd.

•

windlasbiotech.comBSE: 543329NSE: WINDLAS

Market Cap₹ 2,370 Cr.

Current Price

High / Low₹ 1,182 / 697

Stock P/E35.7

Book Value₹ 258

Price to Book2.77

Dividend Yield0.55 %

ROCE16.0 %

ROE12.5 %

Face Value₹ 5

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence

50%

View full sector analysis →

PROS

Company has delivered good profit growth of 67.7% CAGR over last 5 years
Company is almost debt free
Company has delivered good sales growth of 16.2% CAGR over last 5 years
Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.52x)
Company comfortably covers its interest (19.0x coverage)
Company has a consistent dividend-paying track record

CONS

Receivables are growing faster than sales - a possible quality concern
Valuation is stretched - P/E of 35.7 is well above its own 5-year median (23.4)
Growth is decelerating - 3Y profit CAGR (15.9%) trails the 5Y trend (67.7%)
Expensive relative to growth - PEG of 2.2

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs

Part ofNIFTY 50 NIFTY 500 NIFTY LARGEMIDCAP 250 NIFTY 100 NIFTY 200

S.No.	Name
1.	SUNPHARMA	1881.10	37.31	451338.90	0.85	2901.23	26.53	15299.88	10.98	19.11	28.81
2.	DIVISLAB	9570.55	86.86	254068.03	0.31	902.00	65.50	3080.00	27.80	21.51	40.75
3.	TORNTPHARM	4962.75	86.55	188767.06	0.77	566.00	3.28	4921.00	57.32	19.27	33.81
4.	ZYDUSLIFE	1150.00	25.42	114712.94	0.09	990.20	-34.90	8017.00	23.97	21.39	24.54
5.	CIPLA	1383.95	33.17	111803.57	0.94	785.55	-39.18	7119.28	4.13	16.00	16.73
6.	LAURUSLABS	1945.50	96.14	105117.74	0.10	362.07	123.94	2026.31	29.10	18.20	31.50
7.	AUROPHARMA	1686.00	26.13	97008.71	0.24	1032.03	25.22	9150.35	17.44	12.76	20.54
8.	LUPIN	2112.00	17.47	96574.55	0.85	1416.98	16.01	8276.89	34.28	28.86	29.59
9.	DRREDDY	1151.50	29.83	96113.39	0.69	435.60	-69.10	8099.80	-5.21	13.75	10.63
10.	MANKIND	2305.85	46.63	95242.00	0.04	574.09	29.12	4030.59	12.89	13.24	26.30
11.	GLENMARK	2477.35	38.89	69916.93	0.10	482.83	927.88	4018.48	31.35	20.35	20.03
12.	WINDLAS	1148.40	35.66	2369.86	0.55	15.99	-1.79	238.50	17.66	16.06	10.60

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	145	153	162	171	175	187	195	203	210	222	233	238	248
	128	134	142	149	154	164	170	177	184	194	209	213	230
Operating Profit	17	19	20	22	21	23	25	26	27	29	24	25	18
OPM %	11.84%	12.24%	12.53%	12.81%	11.92%	12.33%	12.63%	12.60%	12.62%	12.84%	10.45%	10.58%	7.18%
	3	3	3	4	4	5	4	5	5	4	5	4	5
Interest	0	0	0	0	0	1	1	1	1	1	1	1	2
Depreciation	3	3	3	4	6	6	7	8	7	8	8	8	7
Profit before Tax	16	18	20	23	18	20	20	21	23	24	20	20	23
Tax %	26.19%	23.38%	23.78%	24.87%	26.38%	22.82%	23.74%	21.80%	24.03%	24.54%	24.95%	20.59%	23.03%
Net Profit	12	14	15	17	13	16	15	16	18	18	15	16	18
	5.79	6.75	7.26	8.15	6.47	7.49	7.29	7.77	8.43	8.48	7.09	7.60	8.46

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	315	320	288	329	428	466	513	631	760	904	942
	290	282	244	287	373	413	453	553	666	799	846
Operating Profit	25	38	44	41	55	53	60	78	94	105	96
OPM %	7.87%	11.99%	15.43%	12.61%	12.79%	11.35%	11.74%	12.38%	12.39%	11.58%	10.19%
	4	3	2	2	-29	7	10	13	18	18	18
Interest	5	5	4	3	1	1	1	1	4	5	5
Depreciation	9	11	8	9	13	12	12	13	28	31	31
Profit before Tax	14	25	35	32	11	46	57	77	79	87	87
Tax %	35.03%	32.73%	35.54%	26.31%	55.19%	16.24%	25.26%	24.51%	23.61%	23.58%	23.32%
Net Profit	9	17	22	24	5	39	43	58	61	66	66
EPS	15.58	28.74	37.26	13.00	2.75	18.81	19.71	27.96	28.94	31.48	—
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	19.78%	19.63%	19.67%	20.04%	20.01%	—

COMPOUNDED SALES GROWTH

10 Years:: 13%
5 Years:: 16%
3 Years:: 21%

COMPOUNDED PROFIT GROWTH

10 Years:: 31%
5 Years:: 68%
3 Years:: 16%

STOCK PRICE CAGR

10 Years:: —
5 Years:: 24%
3 Years:: 45%
1 Year:: 14%

RETURN ON EQUITY

10 Years:: 11%
5 Years:: 13%
3 Years:: 13%
Last Year:: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	6	6	6	6	6	11	10	10	10	11
	141	158	188	214	193	382	389	435	490	551
	51	40	30	29	32	6	4	2	29	32
Trade Payables	77	75	58	83	40	63	87	131	178	238
	28	19	13	16	25	26	36	47	52	75
Total Liabilities	303	297	295	349	296	489	527	626	760	907
	56	58	62	70	96	91	109	179	223	213
Capital Work in Progress	15	11	5	0	0	8	14	6	3	56
	121	123	121	127	23	65	107	173	223	268
	40	27	19	49	41	59	75	62	81	62
	0	0	0	0	0	0	0	136	167	227
Cash & Bank	2	6	13	18	31	114	25	31	16	2
	69	73	75	84	104	153	197	38	46	78
Total Assets	303	297	295	349	296	489	527	626	760	907

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	9	44	35	38	18	18	71	109	68	105
Cash from Investing	-39	-11	-7	-14	-20	-154	-14	-92	-74	-92
Cash from Financing	5	-25	-8	-5	1	130	-44	-15	1	-13
	-27	4	7	5	-8	-15	3	2	-5	0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026

Shareholding Pattern

Numbers in percentages

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	62.51	62.51	62.51	62.34	62.34	61.99	61.99	61.90	63.31
	1.59	2.00	1.55	1.52	1.44	1.11	0.93	0.60	2.04
	10.35	9.58	10.26	10.89	11.22	11.44	11.44	11.80	9.84
Government	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	25.55	25.91	25.68	25.25	25.01	25.47	25.64	25.70	24.80

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-01

Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-01 - Windlas Biotech Limited has informed the Exchange about Schedule of meet

2026-08-14

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-14 - Windlas Biotech Limited has informed the Exchange about earnings call transcript of Q1 FY27

2026-08-11

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-11 - Windlas Biotech Limited has informed the Exchange about Link of Recording

2026-08-10

Press Release

2026-08-10 - Windlas Biotech Limited has informed the Exchange regarding a press release dated August 10, 2026, titled "press release on "Windlas Biotech Limited Reports its Q1 FY27 Financial Results"".

2026-08-10

Investor Presentation

2026-08-10 - Windlas Biotech Limited has informed the Exchange about Investor Presentation

2026-08-10

Outcome of Board Meeting

2026-08-10 - Windlas Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

2026-08-05

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-05 - Windlas Biotech Limited has informed the Exchange about Schedule of meet

2026-08-05

Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-05 - Windlas Biotech Limited has informed the Exchange about Schedule of meet

2026-07-24

Shareholders meeting

2026-07-24 - Submission of Combined Voting Results and Scrutinizer s Report under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations ) of the 25th Annual General Meeting held on July 23, 2026

News

Recent coverage and analyst commentary for WINDLAS

Loading news…

🤖

AI Stock Analyst

Windlas Biotech Ltd.

🔒

Sign in to Chat with AI

✨ Sign In to Chat

Free 5nance Account

Name

SUNPHARMA

1881.10

37.31

451338.90

0.85

2901.23

26.53

15299.88

10.98

19.11

28.81

DIVISLAB

9570.55

86.86

254068.03

0.31

902.00

65.50

3080.00

27.80

21.51

40.75

TORNTPHARM

4962.75

86.55

188767.06

0.77

566.00

3.28

4921.00

57.32

19.27

33.81

ZYDUSLIFE

1150.00

25.42

114712.94

0.09

990.20

-34.90

8017.00

23.97

21.39

24.54

CIPLA

1383.95

33.17

111803.57

0.94

785.55

-39.18

7119.28

4.13

16.00

16.73

LAURUSLABS

1945.50

96.14

105117.74

0.10

362.07

123.94

2026.31

29.10

18.20

31.50

AUROPHARMA

1686.00

26.13

97008.71

0.24

1032.03

25.22

9150.35

17.44

12.76

20.54

LUPIN

2112.00

17.47

96574.55

0.85

1416.98

16.01

8276.89

34.28

28.86

29.59

DRREDDY

1151.50

29.83

96113.39

0.69

435.60

-69.10

8099.80

-5.21

13.75

10.63

MANKIND

2305.85

46.63

95242.00

0.04

574.09

29.12

4030.59

12.89

13.24

26.30

GLENMARK

2477.35

38.89

69916.93

0.10

482.83

927.88

4018.48

31.35

20.35

20.03

WINDLAS

1148.40

35.66

2369.86

0.55

15.99

-1.79

238.50

17.66

16.06

10.60

Jun 2023

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

145

153

162

171

175

187

195

203

210

222

233

238

248

128

134

142

149

154

164

170

177

184

194

209

213

230

Operating Profit

OPM %

11.84%

12.24%

12.53%

12.81%

11.92%

12.33%

12.63%

12.60%

12.62%

12.84%

10.45%

10.58%

7.18%

Interest

Depreciation

Profit before Tax

Tax %

26.19%

23.38%

23.78%

24.87%

26.38%

22.82%

23.74%

21.80%

24.03%

24.54%

24.95%

20.59%

23.03%

Net Profit

5.79

6.75

7.26

8.15

6.47

7.49

7.29

7.77

8.43

8.48

7.09

7.60

8.46

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

TTM

315

320

288

329

428

466

513

631

760

904

942

290

282

244

287

373

413

453

553

666

799

846

Operating Profit

105

OPM %

7.87%

11.99%

15.43%

12.61%

12.79%

11.35%

11.74%

12.38%

12.39%

11.58%

10.19%

-29

Interest

Depreciation

Profit before Tax

Tax %

35.03%

32.73%

35.54%

26.31%

55.19%

16.24%

25.26%

24.51%

23.61%

23.58%

23.32%

Net Profit

EPS

15.58

28.74

37.26

13.00

2.75

18.81

19.71

27.96

28.94

31.48

—

Dividend Payout %

0.00%

19.78%

19.63%

19.67%

20.04%

20.01%

—

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

141

158

188

214

193

382

389

435

490

551

Trade Payables

131

178

238

Total Liabilities

303

297

295

349

296

489

527

626

760

907

109

179

223

213

Capital Work in Progress

121

123

121

127

107

173

223

268

136

167

227

Cash & Bank

114

104

153

197

Total Assets

303

297

295

349

296

489

527

626

760

907

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

109

105

Cash from Investing

-39

-11

-7

-14

-20

-154

-14

-92

-74

-92

Cash from Financing

-25

-8

-5

130

-44

-15

-13

-27

-8

-15

-5

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

62.51

62.34

61.99

61.90

63.31

1.59

2.00

1.55

1.52

1.44

1.11

0.93

0.60

2.04

10.35

9.58

10.26

10.89

11.22

11.44

11.80

9.84

Government

0.00

25.55

25.91

25.68

25.25

25.01

25.47

25.64

25.70

24.80

Windlas Biotech Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI

Windlas Biotech Ltd.

AI Sector View

Peer comparison

Quarterly Results

Profit & Loss

Balance Sheet

Corporate actions

Cash Flows

Ratios

Shareholding Pattern

Documents

News

Sign in to Chat with AI